Alvotech further strengthens liquidity by securing term loan facility of $75 million
Alvotech (NASDAQ: ALVO) said it amended its credit agreement to add a $75 million term loan facility maturing Dec. 31, 2027, led by GoldenTree Asset Management. The financing follows a $165 million equity raise on June 18, 2026, bringing total new capital access to $240 million (equity plus undrawn loan). Funds support R&D and global product launches.
How this was made
The 30-second read
Why it matters
The $75M term loan (maturity Dec. 31, 2027) increases total new capital access to $240M when combined with the equity raise and an undrawn term loan facility, intended to fund R&D and global product launches.
Market read
A fresh, disclosed financing package improves liquidity visibility for pipeline and launch execution, which can shift risk perception for a cash-burn biotech.
What to watch
Traders may focus on whether the new debt changes leverage/credit terms versus the equity dilution already incurred, and how quickly management can convert the added capital into FDA/regulatory and commercial traction.
Background
Alvotech recently raised $165M in equity (June 18, 2026) and now expands its credit agreement with GoldenTree and existing lenders.
Ticker impact
Alvotech amended its credit agreement for an additional $75M term loan maturing Dec. 31, 2027, after a $165M equity raise.
Likely supportive for the stock on liquidity/funding-risk relief, with follow-through tied to execution and regulatory milestones.
The article discloses a new $75M term loan (12.50% interest, monthly cash payments) and frames it as strengthening financial position alongside the prior $165M equity raise, which is a concrete balance-sheet catalyst.
Market effects
Adds to biosimilars/biotech financing narrative: continued access to capital for pipeline advancement and commercialization.
Limited direct regional spillover; primarily affects US-listed biotech sentiment and credit perception.
Supports global biosimilar launch execution plans, but the disclosed catalyst is company-specific financing rather than a broad policy shift.
Counterpoint
The facility’s 12.50% cash-pay interest could pressure future cash flow, and the company still faces execution/regulatory uncertainty for pipeline milestones.
Key entities
- companyAlvotech
NASDAQ-listed biosimilars developer and manufacturer that secured an additional $75M term loan facility.
- lenderGoldenTree Asset Management LP
Led the $75M additional term loan facility under Alvotech’s amended credit agreement.
